O	0	7	Overall
O	8	16	Survival
O	17	21	with
B-intervention	22	32	Ribociclib
I-intervention	33	37	plus
I-intervention	38	47	Endocrine
I-intervention	48	55	Therapy
O	56	58	in
O	59	65	Breast
O	66	72	Cancer
O	72	73	.

O	74	76	An
O	77	84	earlier
O	85	93	analysis
O	94	96	of
O	97	101	this
O	102	107	phase
O	108	109	3
O	110	115	trial
O	116	122	showed
O	123	127	that
O	128	131	the
O	132	140	addition
O	141	143	of
O	144	145	a
O	146	152	cyclin
O	152	153	-
O	153	162	dependent
O	163	169	kinase
O	170	171	4
O	172	175	and
O	176	177	6
O	178	179	(
O	179	183	CDK4
O	183	184	/
O	184	185	6
O	185	186	)
O	187	196	inhibitor
O	197	199	to
O	200	209	endocrine
O	210	217	therapy
O	218	226	provided
O	227	228	a
O	229	236	greater
O	237	244	benefit
O	245	249	with
O	250	256	regard
O	257	259	to
O	260	271	progression
O	271	272	-
O	272	276	free
O	277	285	survival
O	286	290	than
O	291	300	endocrine
O	301	308	therapy
O	309	314	alone
O	315	317	in
B-eligibility	318	331	premenopausal
I-eligibility	332	334	or
I-eligibility	335	349	perimenopausal
I-eligibility	350	358	patients
I-eligibility	359	363	with
I-eligibility	364	372	advanced
I-eligibility	373	380	hormone
I-eligibility	380	381	-
I-eligibility	381	389	receptor
I-eligibility	389	390	-
I-eligibility	390	398	positive
I-eligibility	398	399	,
I-eligibility	400	405	human
I-eligibility	406	415	epidermal
I-eligibility	416	422	growth
I-eligibility	423	429	factor
I-eligibility	430	438	receptor
I-eligibility	439	440	2
I-eligibility	441	442	(
I-eligibility	442	446	HER2
I-eligibility	446	447	)
I-eligibility	447	448	-
I-eligibility	448	456	negative
I-eligibility	457	463	breast
I-eligibility	464	470	cancer
I-eligibility	470	471	.

O	472	476	Here
O	477	479	we
O	480	486	report
O	487	490	the
O	491	498	results
O	499	501	of
O	502	503	a
O	504	512	protocol
O	512	513	-
O	513	522	specified
O	523	530	interim
O	531	539	analysis
O	540	542	of
O	543	546	the
O	547	550	key
O	551	560	secondary
O	561	564	end
O	565	570	point
O	571	573	of
B-outcome-Measure	574	581	overall
I-outcome-Measure	582	590	survival
O	590	591	.

O	592	594	We
O	595	603	randomly
O	604	612	assigned
O	613	621	patients
O	622	624	to
O	625	632	receive
O	633	639	either
O	640	650	ribociclib
O	651	653	or
B-control	654	661	placebo
I-control	662	664	in
I-control	665	673	addition
I-control	674	676	to
I-control	677	686	endocrine
I-control	687	694	therapy
O	695	696	(
O	696	705	goserelin
O	706	709	and
O	710	716	either
O	717	718	a
O	719	731	nonsteroidal
O	732	741	aromatase
O	742	751	inhibitor
O	752	754	or
O	755	764	tamoxifen
O	764	765	)
O	765	766	.

O	767	774	Overall
O	775	783	survival
O	784	787	was
O	788	797	evaluated
O	798	802	with
O	803	806	the
O	807	810	use
O	811	813	of
O	814	815	a
O	816	826	stratified
O	827	830	log
O	830	831	-
O	831	835	rank
O	836	840	test
O	841	844	and
O	845	855	summarized
O	856	860	with
O	861	864	the
O	865	868	use
O	869	871	of
O	872	878	Kaplan
O	878	879	-
O	879	884	Meier
O	885	892	methods
O	892	893	.

O	894	895	A
O	896	901	total
O	902	904	of
B-total-participants	905	908	672
O	909	917	patients
O	918	922	were
O	923	931	included
O	932	934	in
O	935	938	the
O	939	948	intention
O	948	949	-
O	949	951	to
O	951	952	-
O	952	957	treat
O	958	968	population
O	968	969	.

O	970	975	There
O	976	980	were
B-iv-bin-abs	981	983	83
B-outcome	984	990	deaths
O	991	996	among
B-intervention-participants	997	1000	335
O	1001	1009	patients
O	1010	1011	(
B-iv-bin-percent	1011	1013	24
I-iv-bin-percent	1013	1014	.
I-iv-bin-percent	1014	1015	8
I-iv-bin-percent	1015	1016	%
O	1016	1017	)
O	1018	1020	in
O	1021	1024	the
O	1025	1035	ribociclib
O	1036	1041	group
O	1042	1045	and
B-cv-bin-abs	1046	1049	109
O	1050	1056	deaths
O	1057	1062	among
B-control-participants	1063	1066	337
O	1067	1075	patients
O	1076	1077	(
B-cv-bin-percent	1077	1079	32
I-cv-bin-percent	1079	1080	.
I-cv-bin-percent	1080	1081	3
I-cv-bin-percent	1081	1082	%
O	1082	1083	)
O	1084	1086	in
O	1087	1090	the
O	1091	1098	placebo
O	1099	1104	group
O	1104	1105	.

O	1106	1109	The
O	1110	1118	addition
O	1119	1121	of
O	1122	1132	ribociclib
O	1133	1135	to
O	1136	1145	endocrine
O	1146	1153	therapy
O	1154	1162	resulted
O	1163	1165	in
O	1166	1179	significantly
O	1180	1186	longer
O	1187	1194	overall
O	1195	1203	survival
O	1204	1208	than
O	1209	1218	endocrine
O	1219	1226	therapy
O	1227	1232	alone
O	1232	1233	.

O	1234	1237	The
O	1238	1247	estimated
B-outcome	1248	1255	overall
I-outcome	1256	1264	survival
I-outcome	1265	1267	at
I-outcome	1268	1270	42
I-outcome	1271	1277	months
O	1278	1281	was
B-iv-bin-percent	1282	1284	70
I-iv-bin-percent	1284	1285	.
I-iv-bin-percent	1285	1286	2
I-iv-bin-percent	1286	1287	%
O	1288	1289	(
O	1289	1291	95
O	1291	1292	%
O	1293	1303	confidence
O	1304	1312	interval
O	1313	1314	[
O	1314	1316	CI
O	1316	1317	]
O	1317	1318	,
O	1319	1321	63
O	1321	1322	.
O	1322	1323	5
O	1324	1326	to
O	1327	1329	76
O	1329	1330	.
O	1330	1331	0
O	1331	1332	)
O	1333	1335	in
O	1336	1339	the
O	1340	1350	ribociclib
O	1351	1356	group
O	1357	1360	and
B-cv-bin-percent	1361	1363	46
I-cv-bin-percent	1363	1364	.
I-cv-bin-percent	1364	1365	0
I-cv-bin-percent	1365	1366	%
O	1367	1368	(
O	1368	1370	95
O	1370	1371	%
O	1372	1374	CI
O	1374	1375	,
O	1376	1378	32
O	1378	1379	.
O	1379	1380	0
O	1381	1383	to
O	1384	1386	58
O	1386	1387	.
O	1387	1388	9
O	1388	1389	)
O	1390	1392	in
O	1393	1396	the
O	1397	1404	placebo
O	1405	1410	group
O	1411	1412	(
O	1412	1418	hazard
O	1419	1424	ratio
O	1425	1428	for
O	1429	1434	death
O	1434	1435	,
O	1436	1437	0
O	1437	1438	.
O	1438	1440	71
O	1440	1441	;
O	1442	1444	95
O	1444	1445	%
O	1446	1448	CI
O	1448	1449	,
O	1450	1451	0
O	1451	1452	.
O	1452	1454	54
O	1455	1457	to
O	1458	1459	0
O	1459	1460	.
O	1460	1462	95
O	1462	1463	;
O	1464	1465	P
O	1466	1467	=
O	1468	1469	0
O	1469	1470	.
O	1470	1475	00973
O	1476	1478	by
O	1479	1482	log
O	1482	1483	-
O	1483	1487	rank
O	1488	1492	test
O	1492	1493	)
O	1493	1494	.

O	1495	1498	The
B-outcome	1499	1507	survival
O	1508	1515	benefit
O	1516	1520	seen
O	1521	1523	in
O	1524	1527	the
O	1528	1536	subgroup
O	1537	1539	of
O	1540	1543	495
O	1544	1552	patients
O	1553	1556	who
O	1557	1565	received
O	1566	1568	an
O	1569	1578	aromatase
O	1579	1588	inhibitor
O	1589	1592	was
O	1593	1603	consistent
O	1604	1608	with
O	1609	1613	that
O	1614	1616	in
O	1617	1620	the
O	1621	1628	overall
O	1629	1638	intention
O	1638	1639	-
O	1639	1641	to
O	1641	1642	-
O	1642	1647	treat
O	1648	1658	population
O	1659	1660	(
O	1660	1666	hazard
O	1667	1672	ratio
O	1673	1676	for
O	1677	1682	death
O	1682	1683	,
O	1684	1685	0
O	1685	1686	.
O	1686	1688	70
O	1688	1689	;
O	1690	1692	95
O	1692	1693	%
O	1694	1696	CI
O	1696	1697	,
O	1698	1699	0
O	1699	1700	.
O	1700	1702	50
O	1703	1705	to
O	1706	1707	0
O	1707	1708	.
O	1708	1710	98
O	1710	1711	)
O	1711	1712	.

O	1713	1716	The
O	1717	1727	percentage
O	1728	1730	of
B-outcome	1731	1739	patients
I-outcome	1740	1743	who
I-outcome	1744	1752	received
I-outcome	1753	1763	subsequent
I-outcome	1764	1778	antineoplastic
I-outcome	1779	1786	therapy
O	1787	1790	was
O	1791	1799	balanced
O	1800	1807	between
O	1808	1811	the
O	1812	1818	groups
O	1819	1820	(
B-iv-bin-percent	1820	1822	68
I-iv-bin-percent	1822	1823	.
I-iv-bin-percent	1823	1824	9
I-iv-bin-percent	1824	1825	%
O	1826	1828	in
O	1829	1832	the
O	1833	1843	ribociclib
O	1844	1849	group
O	1850	1853	and
B-cv-bin-percent	1854	1856	73
I-cv-bin-percent	1856	1857	.
I-cv-bin-percent	1857	1858	2
I-cv-bin-percent	1858	1859	%
O	1860	1862	in
O	1863	1866	the
O	1867	1874	placebo
O	1875	1880	group
O	1880	1881	)
O	1881	1882	.

O	1883	1886	The
O	1887	1891	time
O	1892	1896	from
O	1897	1910	randomization
O	1911	1913	to
B-outcome	1914	1921	disease
I-outcome	1922	1933	progression
O	1934	1940	during
O	1941	1948	receipt
O	1949	1951	of
O	1952	1958	second
O	1958	1959	-
O	1959	1963	line
O	1964	1971	therapy
O	1972	1974	or
O	1975	1977	to
O	1978	1983	death
O	1984	1987	was
O	1988	1992	also
O	1993	1999	longer
O	2000	2002	in
O	2003	2006	the
O	2007	2017	ribociclib
O	2018	2023	group
O	2024	2028	than
O	2029	2031	in
O	2032	2035	the
O	2036	2043	placebo
O	2044	2049	group
O	2050	2051	(
O	2051	2057	hazard
O	2058	2063	ratio
O	2064	2067	for
O	2068	2075	disease
O	2076	2087	progression
O	2088	2090	or
O	2091	2096	death
O	2096	2097	,
O	2098	2099	0
O	2099	2100	.
O	2100	2102	69
O	2102	2103	;
O	2104	2106	95
O	2106	2107	%
O	2108	2110	CI
O	2110	2111	,
O	2112	2113	0
O	2113	2114	.
O	2114	2116	55
O	2117	2119	to
O	2120	2121	0
O	2121	2122	.
O	2122	2124	87
O	2124	2125	)
O	2125	2126	.

O	2127	2131	This
O	2132	2137	trial
O	2138	2144	showed
O	2145	2158	significantly
O	2159	2165	longer
O	2166	2173	overall
O	2174	2182	survival
O	2183	2187	with
O	2188	2189	a
O	2190	2194	CDK4
O	2194	2195	/
O	2195	2196	6
O	2197	2206	inhibitor
O	2207	2211	plus
O	2212	2221	endocrine
O	2222	2229	therapy
O	2230	2234	than
O	2235	2239	with
O	2240	2249	endocrine
O	2250	2257	therapy
O	2258	2263	alone
O	2264	2269	among
O	2270	2278	patients
O	2279	2283	with
O	2284	2292	advanced
O	2293	2300	hormone
O	2300	2301	-
O	2301	2309	receptor
O	2309	2310	-
O	2310	2318	positive
O	2318	2319	,
O	2320	2324	HER2
O	2324	2325	-
O	2325	2333	negative
O	2334	2340	breast
O	2341	2347	cancer
O	2347	2348	.

O	2349	2351	No
O	2352	2355	new
O	2356	2364	concerns
O	2365	2374	regarding
O	2375	2380	toxic
O	2381	2388	effects
O	2389	2396	emerged
O	2397	2401	with
O	2402	2408	longer
O	2409	2415	follow
O	2415	2416	-
O	2416	2418	up
O	2418	2419	.

O	2420	2421	(
O	2421	2427	Funded
O	2428	2430	by
O	2431	2439	Novartis
O	2439	2440	;
O	2441	2450	MONALEESA
O	2450	2451	-
O	2451	2452	7
O	2453	2467	ClinicalTrials
O	2467	2468	.
O	2469	2472	gov
O	2473	2479	number
O	2479	2480	,
O	2481	2492	NCT02278120
O	2492	2493	.
O	2493	2494	)
O	2494	2495	.
